This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Soligenix Announces Collaboration With Infectious Disease Research Institute To Develop Thermostabilized Biodefense Vaccines Utilizing Novel Adjuvants

PRINCETON, N.J., June 27, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that it has entered into a collaboration with the Infectious Disease Research Institute (IDRI) of Seattle, WA to develop select biodefense vaccines using IDRI's potent and safe synthetic adjuvants in conjunction with Soligenix's proprietary subunit proteins and thermostability platform (known as ThermoVax ).  Synthetic adjuvants are immunologically active compounds that are added to vaccines to aid in the induction of enhanced protective immune responses.  IDRI has state of the art expertise in developing and formulating a range of adjuvants that have proven capable of enhancing the level and breadth of cellular and humoral immune responses to a variety of vaccine antigens.  The combination of these technologies has the potential to result in vaccines with robust characteristics for long-term stability and rapid onset of protective immunity, desired features of vaccines that would be stockpiled for emergency use.

The first developmental objective of the collaboration is to assess the combination of one of IDRI's adjuvant compounds that has been shown to enhance the generation of high titer neutralizing antibodies to anthrax toxin with Soligenix's second generation DNI (Dominant Negative Inhibitor) subunit protein anthrax vaccine candidate, known as VeloThrax . VeloThrax is Soligenix's hyperimmunogenic derivative of anthrax rPA (recombinant protective antigen), a candidate vaccine to protect against anthrax disease. Concurrently, the second developmental objective is to assess the combination of an IDRI adjuvant with formulations of RiVax , Soligenix's vaccine against ricin toxin under development. The goal for both vaccines is to achieve stable products that will promote rapid onset of protective immunity in humans to minimize the number of vaccinations required for protective immunity. 

"IDRI is enthusiastic about working with Soligenix to support their efforts in developing their anthrax and ricin vaccine candidates, and are highly confident that IDRI's adjuvant technology can help build effective vaccines," said Darrick Carter PhD, IDRI's Vice President of Adjuvant Technology. "These new candidate vaccines could be the critical solution in providing protection to people in the event there is a bioterror threat from the release of anthrax or ricin toxins." 

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs